CD8A and neoplasm: TIGIT is upregulated on tumor antigen-specific CD8+ T cells and CD8+ tumor-infiltrating lymphocytes in various cancer types and TIGIT receptor/poliovirus receptor (PVR) ligand interaction signaling inhibits cytotoxicity mediated by NK and CD8+ T cells.